RedHill Biopharma plans further GI portfolio expansion to drive commercial growth
RDHL•RedHill Biopharma plans to expand its gastrointestinal drug portfolio with complementary products, while focusing growth efforts on Rebyota and Clenpiq and using its existing infrastructure and physician relationships.
1. Portfolio expansion plans
RedHill Biopharma plans to add complementary products to its gastrointestinal drug portfolio as it targets growth as a commercial specialty pharmaceutical business. Its efforts will focus on Rebyota and Clenpiq, leveraging existing infrastructure, physician relationships and established market demand.
2. Capital allocation
The company said disciplined capital allocation and improved operating economics are intended to support commercial growth and shareholder value.




